血清IL-8作为慢性阻塞性肺疾病中磷酸二酯酶-4抑制剂疗效决定因素的研究
本研究通过ECLIPSE数据集构建血液PDE4基因表达特征,并在BIOMARKER和PIONEER研究中验证。发现血清IL-8是与PDE4信号传导唯一持续相关的变量,较低IL-8水平与更高PDE4活性相关。在PIONEER研究中,低IL-8水平患者接受tanimilast治疗后急性加重率降低幅度更大,且与血嗜酸性粒细胞≥150/μl或慢性支气管炎联合可进一步增加疗效。
要点
- 血清IL-8低水平可预测COPD患者对PDE4抑制剂tanimilast的急性加重预防效果更佳。
- IL-8≤20 pg/ml时tanimilast减少急性加重达36% vs 18%(P=0.035)。
- 联合血嗜酸性粒细胞≥150/μl或慢性支气管炎可进一步增加急性加重率降低幅度。
核心结论
- 血清IL-8是PDE4抑制的独立预测因子,低基线IL-8水平的COPD患者接受tanimilast治疗可更有效预防急性加重。
研究设计与样本
- 利用ECLIPSE研究数据通过无监督聚类构建血液PDE4基因表达特征,并在BIOMARKER研究(血液和痰转录组数据)中验证,最后在2b期PIONEER研究(tanimilast)中测试生物标志物对临床反应的预测性。
主要发现
- 在BIOMARKER研究中,血清IL-8是唯一与PDE4信号传导持续相关的变量,较低IL-8水平与较高PDE4活性相关。
- 在PIONEER研究中,低IL-8水平患者中tanimilast介导的急性加重率降低幅度增加至两倍(36% vs 18%),在≤20 pg/ml时达到统计学显著性(P=0.035)。
- 与血嗜酸性粒细胞≥150/μl或慢性支气管炎联合可进一步增加急性加重率降低幅度:分别为45%(P=0.013)和47%(P=0.027)。
关键数值与推荐
- 血清IL-8≤20 pg/ml时,tanimilast组急性加重率降低36%,对照组降低18%(P=0.035)。
- 联合血嗜酸性粒细胞≥150/μl时,急性加重率降低45%(P=0.013)。
- 联合慢性支气管炎时,急性加重率降低47%(P=0.027)。
临床怎么用
- 对于COPD患者,可考虑检测血清IL-8水平以识别更可能从PDE4抑制剂tanimilast治疗中获益的人群,尤其是低IL-8水平者。
- 联合血嗜酸性粒细胞计数或慢性支气管炎病史可进一步优化患者选择。
局限性
- 需要在其他数据集中验证该生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Phosphodiesterase-4 (PDE4) inhibitors have demonstrated increased efficacy in patients with chronic obstructive pulmonary disease who had chronic bronchitis or higher blood eosinophil counts. Further characterization of patients who are most likely to benefit is warranted. Objective: To identify determinants of response to the PDE4 inhibitor tanimilast. Methods: A PDE4 gene expression signature in blood was developed by unsupervised clustering of the ECLIPSE study dataset (ClinicalTrials.gov ID: NCT00292552; Gene Expression Omnibus Series ID: GSE76705). The signature was further evaluated using blood and sputum transcriptome data from the BIOMARKER study (NCT03004417; GSE133513), enabling validation of the association between PDE4 signaling and target biomarkers. Predictivity of the associated biomarkers against clinical response was then tested in the phase-2b PIONEER tanimilast study (NCT02986321). Measurements and Main Results: The PDE4 gene expression signature developed in the ECLIPSE dataset classified subgroups of patients associated with different PDE4 signaling in the BIOMARKER cohort with an area under the receiver operator curve of 98%. In the BIOMARKER study, serum IL-8 was the only variable that was consistently associated with PDE4 signaling, with lower levels associated with higher PDE4 activity. In the PIONEER study, the exacerbation rate reduction mediated by tanimilast treatment increased up to twofold in patients with lower IL-8 levels; 36% versus 18%, reaching statistical significance at ⩽20 pg/ml (P = 0.035). The combination with blood eosinophils ⩾150 μl-1 or chronic bronchitis provided further additive exacerbation rate reduction: 45% (P = 0.013) and 47% (P = 0.027), respectively. Conclusions: Using selected heterogeneous datasets, this analysis identifies IL-8 as an independent predictor of PDE4 inhibition, as tanimilast had a greater effect on exacerbation prevention in patients with chronic obstructive pulmonary disease who had lower baseline serum IL-8 levels. Testing of this biomarker in other datasets is warranted. Clinical trial registered with www.clinicaltrials.gov (NCT00292552 [Gene Expression Omnibus Series ID: GSE76705], NCT03004417 [GSE133513], and NCT02986321).
引用
- Govoni M, Bassi M, Santoro D, et al. Serum IL-8 as a Determinant of Response to Phosphodiesterase-4 Inhibition in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2023. PMID: 37192443. doi:10.1164/rccm.202301-0071OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。